An observational study in Chronic Kidney Disease, sponsored by Fresenius Kabi. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-05.
Sponsored by Fresenius Kabi · Observational
The purpose of this study is to characterize the patient and disease profile under the influence of a protein-restricted diet supplemented with keto acids/amino acids (KA/AA), focusing on the progression of chronic renal insufficiency, calcium and phosphorus metabolism, nutritional status, patient compliance to diet and Ketosteril intake as well as the persistent dietary education to ensure compliance in a large group of pre-dialysis patients.
3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.
This study's enrollment of 154 is below the median of 192 across 1,033 observational studies indexed under Kidney Diseases.
Browse Kidney Diseases studies →Fresenius Kabi is the lead sponsor of 51 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Pre-dialytic chronic kidney disease patients treated at nephrology units of selected hospitals in China
Exclusion Criteria:
Observational study: supplemented protein-restricted diet
Other: Observational study: Supplemented protein-restricted diet
Observational study: Supplemented protein-restricted diet
Patient compliance to Ketosteril (number of tablets taken; patient reported)
This is an observational study aiming to characterise the patient profile and contemporary treatment of pre-dialytic chronic kidney disease (CKD) in patients receiving a restricted protein diet supplemented with Ketosteril®. There is no distinction between primary and secondary outcome measures in the observational plan, and only Routine procedures are documented. Patient compliance to Ketosteril will be assessed daily, for a total of 12 months.
Time frame: 12 months
Patient compliance to diet (protein and energy intake; investigator and patient-reported, based on patient diary and a routine 3-day food diary)
This is an observational study aiming to characterise the patient profile and contemporary treatment of pre-dialytic chronic kidney disease (CKD) in patients receiving a restricted protein diet supplemented with Ketosteril®. There is no distinction between primary and secondary outcome measures in the observational plan, and only Routine procedures are documented.
Time frame: Monthly, starting 1 month after enrolment, for a total of 12 months
CKD stage (according to Kidney Disease Improving Global Outcomes [KDIGO] guideline)
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Presence of comorbidities
Time frame: At baseline
Serum creatinine
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
24h urinary protein
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Urinary microalbumin
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Serum urea
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Creatinine clearance
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Glomerular Filtration Rate (GFR)
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Estimated GFR (eGFR)
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Fasting blood glucose
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Fasting plasma glucose
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Haemoglobin A1c (HbA1c)
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Serum triglyceride
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Serum cholesterol
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Serum high-density lipoprotein (HDL)
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Serum low-density lipoprotein (LDL)
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Serum calcium
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Serum phosphate
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Serum parathyroid hormone (PTH)
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Body weight
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Skinfold thickness
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Serum total protein
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Serum albumin
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Serum prealbumin
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Body mass index (BMI)
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Subjective global assessment (SGA)
Time frame: At baseline and 3, 6, 9 and 12 months after enrolment
Decline in eGFR
Time frame: At 3, 6, 9 and 12 months after enrolment
Worsening of CKD stage
Time frame: At 3, 6, 9 and 12 months after enrolment
Start of dialysis
Time frame: At 3, 6, 9 and 12 months after enrolment
Presence of a 50% reduction in eGFR
Time frame: At 3, 6, 9 and 12 months after enrolment
Serum bicarbonate
Time frame: At baseline and 3, 6 and 12 months after enrolment
Serum haemoglobin
Time frame: At baseline and 3, 6 and 12 months after enrolment
Serum potassium
Time frame: At baseline and 3, 6 and 12 months after enrolment
Reported nausea and vomiting
Time frame: At baseline and 3, 6 and 12 months after enrolment
Presence of concomitant disease
Time frame: At 3, 6, 9 and 12 months after enrolment
Administration of concomitant medication
Time frame: At 3, 6, 9 and 12 months after enrolment
Discontinuation of diet and Ketosteril with the reasons for discontinuation as reported by the investigator
Time frame: Monthly starting at 1 month after enrolment for up to 12 months
Acceptance of diet as documented in the patient diary
Time frame: Daily for up to 12 months
Appetite change as documented in the patient diary
Time frame: Daily for up to 12 months
Change of food intake as documented in the patient diary
Time frame: Daily for up to 12 months
Adverse events including adverse drug reactions and serious adverse events
Time frame: At 3, 6, 9 and 12 months after enrolment
Blood pressure
Time frame: At baseline and 3, 6, 9 and at 12 months after enrolment
Heart rate
Time frame: At baseline and 3, 6, 9 and at 12 months after enrolment
Body temperature
Time frame: At baseline and 3, 6, 9 and at 12 months after enrolment
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fresenius Kabi